Provided by Tiger Trade Technology Pte. Ltd.

Eupraxia Pharmaceuticals

6.68
-0.6850-9.31%
Post-market: 6.680.00000.00%19:56 EDT
Volume:174.23K
Turnover:1.20M
Market Cap:441.04M
PE:-6.70
High:7.45
Open:7.38
Low:6.67
Close:7.36
52wk High:9.32
52wk Low:5.12
Shares:66.07M
Float Shares:54.50M
Volume Ratio:0.33
T/O Rate:0.32%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9967
EPS(LYR):-1.0300
ROE:-66.70%
ROA:-43.66%
PB:4.33
PE(LYR):-6.48

Loading ...

Eupraxia Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference

GlobeNewswire
·
May 28

Stifel Initiates Eupraxia Pharmaceuticals at Buy With CA$34.37 Price Target

MT Newswires Live
·
May 21

Eupraxia Pharmaceuticals Inc : Stifel Initiates Coverage With Buy Rating; Target Price $25

THOMSON REUTERS
·
May 21

Eupraxia Pharmaceuticals initiated with a Buy at Stifel

TIPRANKS
·
May 21

Eupraxia Pharmaceuticals Reports Stronger Balance Sheet but Wider Q1 2026 Loss in Form 6-K Filing

TIPRANKS
·
May 13

Eupraxia Pharmaceuticals reports Q1 net loss ($12.7M) vs. ($6.8M) last year

TIPRANKS
·
May 13

Eupraxia Pharmaceuticals Q1 EPS $(0.23) Misses $(0.22) Estimate

Benzinga Earnings
·
May 13

Eupraxia Pharmaceuticals Reports First Quarter 2026 Financial Results

GlobeNewswire
·
May 13

Eupraxia Pharmaceuticals Reports EREFS Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week (DDW)

GlobeNewswire
·
May 05

Eupraxia Pharmaceuticals Price Target Maintained With a $11.00/Share by HC Wainwright & Co.

Dow Jones
·
May 05

H.C. Wainwright Remains a Buy on Eupraxia Pharmaceuticals (EPRX)

TIPRANKS
·
May 04

Eupraxia Pharmaceuticals Appoints Dr. Jeymi Tambiah as Chief Medical Officer

GlobeNewswire
·
May 02

Eupraxia Pharmaceuticals Price Target Maintained With a $11.00/Share by HC Wainwright & Co.

Dow Jones
·
Apr 22

Eupraxia Pharmaceuticals to Present at Digestive Disease Week Annual Meeting

GlobeNewswire
·
Apr 22

Craig-Hallum Sticks to Their Buy Rating for Eupraxia Pharmaceuticals (EPRX)

TIPRANKS
·
Apr 22

Eupraxia Pharmaceuticals Reports Positive Nine-Month Tissue Health and Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis

GlobeNewswire
·
Apr 21

Eupraxia Pharmaceuticals to Highlight Drug-Delivery Pipeline at April Investor Conferences

TIPRANKS
·
Apr 15

Eupraxia Pharmaceuticals to Present at Upcoming Investor Conferences

GlobeNewswire
·
Apr 13

Eupraxia Pharmaceuticals (EPRX) Receives a Buy from Cantor Fitzgerald

TIPRANKS
·
Apr 01

Eupraxia Pharmaceuticals Boasts $900 Million Peak Sales Potential: Analyst

Benzinga_recent_news
·
Mar 24